These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34474469)

  • 1. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma.
    Ferrari N; Ward G; Gewinner C; Davis MP; Jueliger S; Saini H; Munck J; Smyth T; Ferraldeschi R; Keer H; Lyons J; Sims MJ
    Blood Adv; 2021 Oct; 5(20):4003-4016. PubMed ID: 34474469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma.
    Ward GA; Zhang Z; Jueliger S; Potapov IS; Davis MP; Boxall AR; Taylor J; Keer H; Biondo A; Lyons JF; Sims M; Smyth T
    Cancer Res Commun; 2024 Jun; 4(6):1441-1453. PubMed ID: 38727208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.
    Crawford N; Stott KJ; Sessler T; McCann C; McDaid W; Lees A; Latimer C; Fox JP; Munck JM; Smyth T; Shah A; Martins V; Lawler M; Dunne PD; Kerr EM; McDade SS; Coyle VM; Longley DB
    Mol Cancer Ther; 2021 Sep; 20(9):1627-1639. PubMed ID: 34389694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis.
    Knoll G; Ehrenschwender M
    FEBS Open Bio; 2021 Mar; 11(3):714-723. PubMed ID: 33484626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer.
    Ye W; Gunti S; Allen CT; Hong Y; Clavijo PE; Van Waes C; Schmitt NC
    Oncoimmunology; 2020; 9(1):1710398. PubMed ID: 32002309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel smac mimetic ASTX660 (Tolinapant) and TNF-α synergistically induce necroptosis in bladder cancer cells in vitro upon apoptosis inhibition.
    Wang L; Hu C; Zhao Y; Hu X
    Biochem Biophys Res Commun; 2022 Apr; 602():8-14. PubMed ID: 35247703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways.
    Dittmann J; Haydn T; Metzger P; Ward GA; Boerries M; Vogler M; Fulda S
    Cell Death Differ; 2020 Jun; 27(6):1878-1895. PubMed ID: 31831875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma.
    Mita MM; LoRusso PM; Papadopoulos KP; Gordon MS; Mita AC; Ferraldeschi R; Keer H; Oganesian A; Su XY; Jueliger S; Tolcher AW
    Clin Cancer Res; 2020 Jun; 26(12):2819-2826. PubMed ID: 31900279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV
    Xiao R; An Y; Ye W; Derakhshan A; Cheng H; Yang X; Allen C; Chen Z; Schmitt NC; Van Waes C
    Clin Cancer Res; 2019 Nov; 25(21):6463-6474. PubMed ID: 31266830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
    Ward GA; Lewis EJ; Ahn JS; Johnson CN; Lyons JF; Martins V; Munck JM; Rich SJ; Smyth T; Thompson NT; Williams PA; Wilsher NE; Wallis NG; Chessari G
    Mol Cancer Ther; 2018 Jul; 17(7):1381-1391. PubMed ID: 29695633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.
    Witzig TE; Reeder C; Han JJ; LaPlant B; Stenson M; Tun HW; Macon W; Ansell SM; Habermann TM; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Colgan JP; Markovic S; Nowakowski GS; Gupta M
    Blood; 2015 Jul; 126(3):328-35. PubMed ID: 25921059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
    He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose escalation of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer : a study protocol for a phase 1b TiTE-CRM clinical trial (CRAIN) in UK secondary care centres.
    Hoskin P; Lee M; Dunkley D; Danh M; Wickens R; Saunders G; Northey J; Crabb S; McFarlane V; Sadozye A; Cooper R; Mathew T; Haslett K; Reeves K; Reed R; Bigos K; Williams KJ; Rowling E; Choudhury A; Dancer S; Smith D; Griffiths G
    BMC Cancer; 2024 Jun; 24(1):702. PubMed ID: 38849715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660).
    Johnson CN; Ahn JS; Buck IM; Chiarparin E; Day JEH; Hopkins A; Howard S; Lewis EJ; Martins V; Millemaggi A; Munck JM; Page LW; Peakman T; Reader M; Rich SJ; Saxty G; Smyth T; Thompson NT; Ward GA; Williams PA; Wilsher NE; Chessari G
    J Med Chem; 2018 Aug; 61(16):7314-7329. PubMed ID: 30091600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New targets of therapy in T-cell lymphomas.
    Erter J; Alinari L; Darabi K; Gurcan M; Garzon R; Marcucci G; Bechtel MA; Wong H; Porcu P
    Curr Drug Targets; 2010 Apr; 11(4):482-93. PubMed ID: 20196721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
    Horwitz SM; Koch R; Porcu P; Oki Y; Moskowitz A; Perez M; Myskowski P; Officer A; Jaffe JD; Morrow SN; Allen K; Douglas M; Stern H; Sweeney J; Kelly P; Kelly V; Aster JC; Weaver D; Foss FM; Weinstock DM
    Blood; 2018 Feb; 131(8):888-898. PubMed ID: 29233821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.
    Ravi D; Bhalla S; Gartenhaus RB; Crombie J; Kandela I; Sharma J; Mazar A; Evens AM
    Clin Cancer Res; 2014 Dec; 20(23):6023-33. PubMed ID: 25316819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panniculitic primary cutaneous gamma delta T-cell lymphoma with concomitant features of autoimmune disease emphasizing a pathophysiologic continuum of lupus profundus with the panniculitic T cell lymphomas.
    Magro CM; Kalomeris T; Dillard A
    Clin Dermatol; 2023; 41(6):680-691. PubMed ID: 37716581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
    Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
    Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma.
    Gibson JF; Alpdogan O; Subtil A; Girardi M; Wilson LD; Roberts K; Foss F
    J Am Acad Dermatol; 2015 Jun; 72(6):1010-5.e5. PubMed ID: 25981001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.